This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McKay, J. D. Articles by Grönberg, H. Search for Related Content PubMed PubMed Citation Articles by McKay, J. D. Articles by Grönberg, H.

Haplotype-Based Analysis of Common Variation in the Growth Hormone Receptor Gene and Prostate Cancer Risk

¹ International Agency for Research on Cancer, Lyons, France; ² Menzies Research Institute, Hobart, Tasmania, Australia; ³ Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University Hospital, Umeå, Sweden; ⁴ German Cancer Research Center, Heidelberg, Germany; and ⁵ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

Requests for reprints: Rudolf Kaaks, Division of Cancer Epidemiology, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. Phone: 49-6221-422219; Fax: 49-6221-422203. E-mail: r.kaaks{at}dkfz.de

The growth hormone receptor (GHR) is potentially involved in prostate cancer through its role in stimulating insulin-like growth factor I production and its cellular effects on prostate epithelium. We have used a haplotype-based tagging approach within CAncer Prostate Sweden, a large retrospective case-control study of 2,863 cases and 1,737 controls to investigate if genetic variation in the GHR gene influences prostate cancer risk. One haplotype in the 3' region of the GHR gene was found associated with prostate cancer risk in elderly men (>65 years old at the time of diagnosis), with heterozygote haplotype carriers having an odds ratio of 1.65 (95% confidence interval, 1.21-2.16; P = 0.0009, P_corrected = 0.03). GHR function has been implicated in the determination of body mass index. Interestingly, the same haplotype associated with risk in the 3' end of the GHR gene was also associated with a decrease in body mass index in controls (P = 0.003, P_corrected = 0.05), possibly indicating some functionality with this haplotype. These results suggest that whereas genetic variation in the GHR gene does not seem to play a major role in prostate cancer etiology, one haplotype in the 3' region may be potentially relevant to cases with later onset of prostate cancer. (Cancer Epidemiol Biomarkers Prev 2007;16(1):169–73)

This article has been cited by other articles:

				G. Cao, H. Lu, J. Feng, J. Shu, D. Zheng, and Y. Hou Lung Cancer Risk Associated with Thr495Pro Polymorphism of GHR in Chinese Population Jpn. J. Clin. Oncol., April 1, 2008; 38(4): 308 - 316. [Abstract] [Full Text] [PDF]